Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.03 Million SEK | 124.92% |
| 2022 | -16.18 Million SEK | -176.07% |
| 2021 | 21.27 Million SEK | 1093.79% |
| 2020 | -2.14 Million SEK | 86.35% |
| 2019 | -15.68 Million SEK | 36.19% |
| 2018 | -24.58 Million SEK | -33.91% |
| 2017 | -18.35 Million SEK | -219.51% |
| 2016 | -5.74 Million SEK | -2816648.53% |
| 2015 | 204.00 SEK | 15.91% |
| 2014 | 176.00 SEK | -99.99% |
| 2013 | 1.71 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.41 Million SEK | -508.59% |
| 2023 Q2 | 3.88 Million SEK | 235.78% |
| 2023 FY | 4.03 Million SEK | 124.92% |
| 2023 Q1 | -2.85 Million SEK | 52.9% |
| 2023 Q4 | 2.3 Million SEK | 172.34% |
| 2023 Q3 | 846 Thousand SEK | -78.21% |
| 2022 Q2 | 2.32 Million SEK | 521.82% |
| 2022 Q1 | -550 Thousand SEK | -116.71% |
| 2022 FY | -16.18 Million SEK | -176.07% |
| 2022 Q4 | -6.07 Million SEK | 55.35% |
| 2022 Q3 | -13.59 Million SEK | -685.99% |
| 2021 Q2 | 16.18 Million SEK | 1218.39% |
| 2021 Q1 | 1.22 Million SEK | 154.7% |
| 2021 FY | 21.27 Million SEK | 1093.79% |
| 2021 Q4 | 3.29 Million SEK | 518.86% |
| 2021 Q3 | 532 Thousand SEK | -96.71% |
| 2020 Q3 | 329.56 Thousand SEK | -89.4% |
| 2020 FY | -2.14 Million SEK | 86.35% |
| 2020 Q4 | -2.24 Million SEK | -781.0% |
| 2020 Q2 | 3.1 Million SEK | 193.23% |
| 2020 Q1 | -3.33 Million SEK | 25.66% |
| 2019 Q4 | -4.48 Million SEK | -14.25% |
| 2019 FY | -15.68 Million SEK | 36.19% |
| 2019 Q1 | -4.86 Million SEK | 43.09% |
| 2019 Q2 | -2.41 Million SEK | 50.39% |
| 2019 Q3 | -3.92 Million SEK | -62.68% |
| 2018 FY | -24.58 Million SEK | -33.91% |
| 2018 Q4 | -8.54 Million SEK | -0.79% |
| 2018 Q3 | -8.47 Million SEK | -345.05% |
| 2018 Q2 | -1.9 Million SEK | 66.3% |
| 2018 Q1 | -5.65 Million SEK | 19.94% |
| 2017 Q1 | -963.23 Thousand SEK | 83.15% |
| 2017 FY | -18.35 Million SEK | -219.51% |
| 2017 Q4 | -7.06 Million SEK | 11.11% |
| 2017 Q3 | -7.94 Million SEK | -232.75% |
| 2017 Q2 | -2.38 Million SEK | -147.88% |
| 2016 Q3 | -1.21 Million SEK | 18.44% |
| 2016 Q1 | 2.67 Million SEK | 1062.46% |
| 2016 FY | -5.74 Million SEK | -2816648.53% |
| 2016 Q2 | -1.48 Million SEK | -155.69% |
| 2016 Q4 | -5.71 Million SEK | -370.65% |
| 2015 Q4 | 230 Thousand SEK | 131.49% |
| 2015 Q3 | -730.36 Thousand SEK | 0.0% |
| 2015 FY | 204.00 SEK | 15.91% |
| 2014 FY | 176.00 SEK | -99.99% |
| 2013 FY | 1.71 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 105.181% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 96.104% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 96.104% |
| Arcoma AB | 2.56 Million SEK | -57.273% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 102.914% |
| BICO Group AB (publ) | -835.7 Million SEK | 100.483% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 83.855% |
| CellaVision AB (publ) | 130.3 Million SEK | 96.905% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 105.054% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 113.816% |
| C-Rad AB (publ) | 35.52 Million SEK | 88.65% |
| Duearity AB (publ) | -26.19 Million SEK | 115.397% |
| Dignitana AB (publ) | -17.36 Million SEK | 123.225% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 104.254% |
| Getinge AB (publ) | 2.41 Billion SEK | 99.833% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 105.932% |
| Iconovo AB (publ) | -45.89 Million SEK | 108.787% |
| Luxbright AB (publ) | -25.37 Million SEK | 115.891% |
| Mentice AB (publ) | -2.81 Million SEK | 243.148% |
| OssDsign AB (publ) | -130.49 Million SEK | 103.09% |
| Paxman AB (publ) | 8.33 Million SEK | 51.591% |
| Promimic AB (publ) | -9.22 Million SEK | 143.727% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 102.521% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 107.255% |
| ScandiDos AB (publ) | -14.64 Million SEK | 127.531% |
| Sectra AB (publ) | 428.38 Million SEK | 99.059% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 106.765% |
| Senzime AB (publ) | -134.14 Million SEK | 103.006% |
| SpectraCure AB (publ) | -20.44 Million SEK | 119.727% |
| Stille AB | 26.64 Million SEK | 84.866% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 100.105% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 95.608% |